Vimian Group AB (publ) (VIMGF)
| Market Cap | 1.98B +14.6% |
| Revenue (ttm) | 515.14M +11.5% |
| Net Income | 42.04M +61.4% |
| EPS | 0.08 +74.1% |
| Shares Out | n/a |
| PE Ratio | 47.00 |
| Forward PE | 29.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 569 |
| Open | 2.770 |
| Previous Close | 3.010 |
| Day's Range | 2.770 - 2.770 |
| 52-Week Range | 2.770 - 4.500 |
| Beta | 1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 17, 2026 |
About Vimian Group AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under... [Read more]
Financial Performance
In 2025, Vimian Group AB's revenue was 425.10 million, an increase of 13.42% compared to the previous year's 374.80 million. Earnings were 31.30 million, an increase of 69.19%.
Financial numbers in EUR Financial StatementsNews
Vimian Group AB Earnings Call Transcript: Q2 2026
Q2 2026 saw 17% revenue growth and strong margin expansion, with all segments contributing to double-digit organic growth. Four acquisitions were closed year-to-date, and the M&A pipeline remains robust. The company received an MSCI ESG rating upgrade to AAA.
Vimian Group AB Slides: Q2 2026
Vimian Group AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 17, 2026.
Vimian Group AB Quarterly report: Q2 2026
Vimian Group AB has published its Q2 2026 quarterly earnings report on July 17, 2026.
Vimian Group AB Earnings Call Transcript: Q1 2026
Q1 2026 saw 8% revenue growth and double-digit expansion in three of four segments, driven by strong organic performance and strategic acquisitions. Margin pressure from investments is expected to normalize as revenue ramps up, with continued focus on M&A and new market entries.
Vimian Group AB Quarterly report: Q1 2026
Vimian Group AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
Vimian Group AB Slides: Q1 2026
Vimian Group AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Vimian price target lowered to SEK 25 from SEK 27 at Barclays
Barclays analyst Hassan Al-Wakeel lowered the firm’s price target on Vimian (VIMGF) to SEK 25 from SEK 27 and keeps an Underweight rating on the shares.
Vimian Group AB Earnings Call Transcript: Q4 2025
Delivered 13% revenue and 11% adjusted EBITDA growth for 2025, with strong Q4 results and margin expansion. Specialty Pharma, MedTech Dental, and Veterinary Services led growth, while U.S. MedTech Orthopedics remains in transition. Robust cash flow and active M&A pipeline support a positive 2026 outlook.
Vimian Group AB Annual report: Q4 2025
Vimian Group AB has published its Q4 2025 annual report on February 12, 2026.
Vimian Group AB Quarterly report: Q4 2025
Vimian Group AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Vimian Group AB Slides: Q4 2025
Vimian Group AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Vimian Group AB Earnings Call Transcript: Q3 2025
Q3 saw 19% revenue growth and 17% adjusted EBITDA growth, with strong results in Specialty Pharma and Veterinary Services, and MedTech returning to organic growth. M&A remains a key strategy, and a $40.2 million court award boosted financials.
Vimian Group AB Quarterly report: Q3 2025
Vimian Group AB has published its Q3 2025 quarterly earnings report on October 22, 2025.
Vimian Group AB Slides: Q3 2025
Vimian Group AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 22, 2025.